Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary? - Scorecard - MDSpire

Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

  • By

  • Conrad Leitsmann

  • Alexander Stephan Reese

  • Richard Zigeuner

  • Hanna Zurl

  • Klara Pohl

  • Johannes Mischinger

  • Iva Simunovic

  • Carl Ketterer

  • Florestan Koll

  • Sebastian Mannweiler

  • Marianne Leitsmann

  • Sascha Ahyai

  • June 12, 2026

  • 0 min

Share

Clinical Scorecard: Assessing the Necessity of Transurethral Resection in Cases of Suspected Primary Bladder Cancer: Insights on Tumor Histology and Clinical Significance

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with suspected bladder cancer undergoing elective TURBT procedures.
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Evaluate interobserver congruence and preoperative findings.
      • Implement specific follow-up protocols based on TURBT results.

      Risks

        Patient & Prescribing Data

        Patients referred for TURBT by board-certified urologists.

        Standard TURBT performed according to current guidelines.

        Clinical Best Practices

        • additional_strategies

        Related Resources & Content

        Original Source(s)

        Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

        • by Conrad Leitsmann, Alexander Stephan Reese, Richard Zigeuner, Hanna Zurl, Klara Pohl, Johannes Mischinger, Iva Simunovic, Carl Ketterer, Florestan Koll, Sebastian Mannweiler, Marianne Leitsmann, Sascha Ahyai

        • June 12, 2026

        Related Content

        Case Report: Not all signet rings are of gastric origin: a case of lobular breast carcinoma metastatic to the stomach

        L-arginine metabolism in breast cancer: mechanisms and therapeutic targets

        Editorial: Cancer Immunosurveillance